跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
公共衛生學院
臺北醫學大學
電話
+886-2-2736-1661 Ext. 6501 to 6503
電子郵件
[email protected]
網站
http://cphn.tmu.edu.tw/
郵寄地址
在地圖上顯示
No. 250 Wu-Xing Street
11031
Taipei
概覽
指紋
網路
專家檔案
(56)
專案
(942)
研究成果
(5509)
資料集
(160)
活動
(1)
指紋
查看啟用 公共衛生學院 的研究主題。這些主題標籤來自此機構會員的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Meta-Analysis
100%
Systematic Review
63%
Cohort Analysis
61%
Randomized Controlled Trial
57%
Apoplexy
50%
Disease
38%
Odds Ratio
38%
Malignant Neoplasm
35%
Hazard Ratio
32%
Prevalence
32%
Injury
30%
Breast Cancer
29%
Diabetes
24%
Infection
23%
Logistic Regression Analysis
21%
Chronic Kidney Disease
20%
Traumatic Brain Injury
18%
COVID-19
18%
Brain Ischemia
17%
Diabetes Mellitus
16%
Body Mass Index
16%
Neoplasm
16%
Cross Sectional Study
15%
Urinary System
15%
Medicine
15%
Programmed Cell Death
15%
Cancer Cell
14%
Health Care Cost
13%
Maturity Onset Diabetes of the Young
13%
Retrospective Cohort Study
13%
Particular Matter 2.5
13%
Health Care
13%
Symptom
13%
Cardiovascular Disease
12%
Public Health
12%
Proportional Hazards Model
12%
Disability
12%
Drug Therapy
11%
Quality of Life
11%
Lung Cancer
11%
Rehabilitation Engineering
11%
Hepatocellular Carcinoma
10%
Mortality Rate
10%
Metastatic Carcinoma
10%
Biological Marker
10%
Childbirth
10%
Chronic Obstructive Pulmonary Disease
10%
In Vitro
10%
Case-Control Study
9%
Global Disease Burden
9%
Adverse Event
9%
Health Survey
9%
Multidrug Resistant Tuberculosis
9%
Ischemic Heart Disease
9%
Network Meta-Analysis
9%
Middle Age
9%
Methylation
9%
Computer Assisted Tomography
9%
Cancer Risk
9%
Atmospheric Aerosol
8%
Blood Pressure
8%
Cohort Effect
8%
Diagnosis
8%
Outpatient
8%
Cardiovascular System
8%
Asthma
8%
Human Immunodeficiency Virus
8%
Survival Rate
7%
Kidney Function
7%
Emergency Department
7%
Retrospective Study
7%
Cesarean Section
7%
Surgeon
7%
Supplementation
7%
Metabolic Syndrome
7%
Cytotoxicity
7%
Glioblastoma
6%
Magnetic Resonance Imaging
6%
Anemia
6%
Long-Term Care
6%
Random Effects Model
6%
Dietary Pattern
6%
Surgery
6%
Adolescent
6%
Cerebral Hemorrhage
6%
Lung Tuberculosis
6%
Patient with Diabetes
6%
End Stage Renal Disease
6%
Cigarette Smoking
6%
Parkinson's Disease
6%
Kawasaki Disease
6%
Recurrent Disease
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Transitional Cell Carcinoma
6%
Signal Transduction
6%
Pediatrics
6%
Closed Head Injury
6%
Population
6%
Prospective Cohort Study
6%
Diseases
6%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
78%
Malignant Neoplasm
59%
Disease
54%
Randomized Controlled Trial
43%
Mouse
31%
Inflammation
29%
Prevalence
29%
Breast Cancer
27%
Injury
27%
Neoplasm
26%
Chronic Kidney Failure
25%
Infection
23%
Diabetes Mellitus
19%
Reactive Oxygen Metabolite
18%
Liver Cell Carcinoma
18%
Nitric Oxide
17%
Cytotoxicity
16%
Adverse Event
16%
Cardiovascular Disease
16%
Brain Ischemia
16%
Biological Marker
15%
Lipopolysaccharide
15%
Lung Cancer
14%
Chronic Obstructive Lung Disease
14%
Transitional Cell Carcinoma
14%
Traumatic Brain Injury
13%
Cyclooxygenase 2
13%
Case-Control Study
13%
Antioxidant
13%
Tumor Necrosis Factor
12%
Comorbidity
12%
Protein P53
12%
Caspase 3
11%
Glioblastoma
11%
Chemotherapy
11%
All Cause Mortality
11%
Hemodialysis
11%
Mortality Rate
10%
Non Insulin Dependent Diabetes Mellitus
10%
Inducible Nitric Oxide Synthase
10%
Colon Cancer
10%
Heme Oxygenase 1
10%
Colorectal Cancer
10%
Cigarette Smoking
10%
Long Term Exposure
9%
Survival Rate
9%
Symptom
9%
Vaccination Policy
9%
Sleep Disordered Breathing
9%
Phosphotransferase
9%
Ischemic Heart Disease
9%
Asthma
9%
Anti-Inflammatory Drug
9%
Well Water
8%
Rheumatoid Arthritis
8%
Mitogen Activated Protein Kinase
8%
Bladder Cancer
8%
Diseases
8%
Nicotinic Receptor
8%
Epidermal Growth Factor Receptor
8%
Western Blot
8%
Parkinson's Disease
8%
Hepatitis C Virus
8%
Overall Survival
7%
Antivirus Agent
7%
Global Disease Burden
7%
Clinical Trial
7%
Interleukin 6
7%
Cytokine
7%
Glutathione
7%
Observational Study
7%
End Stage Renal Disease
7%
Carcinogenesis
7%
Low Birth Weight
7%
HIV
7%
Placebo
7%
Head Injury
6%
Hyperlipidemia
6%
Combination Therapy
6%
Recurrent Disease
6%
Prostaglandin E2
6%
Polycyclic Aromatic Hydrocarbon
6%
Prostate Cancer
6%
Metabolic Syndrome X
6%
Dose-Response Relationship
6%
Rifampicin
6%
Prospective Study
6%
Liver Cancer
6%
Hepatitis C
6%
Gout
6%
Antiinflammatory Activity
6%
Cardiovascular Mortality
6%
Ethanol
6%
12-O-Tetradecanoylphorbol-13-Acetate
6%
Multi-Drug-Resistant Tuberculosis
6%
SARS Coronavirus
5%
C Reactive Protein
5%
Cardiovascular Risk
5%
Cardiovascular Disease
5%
Cell Viability
5%
Nursing and Health Professions
Confidence Interval
71%
Meta Analysis
71%
Systematic Review
44%
Odds Ratio
41%
Cohort Analysis
34%
Injury
29%
Disease
27%
Prevalence
25%
Quality of Life
25%
Traumatic Brain Injury
24%
National Health Insurance
21%
Logistic Regression Analysis
21%
World Health Organization
21%
Cross-Sectional Study
21%
Rehabilitation Engineering
18%
Hazard Ratio
18%
Disability
16%
Breast Cancer
14%
Symptom
14%
Drug Therapy
14%
Practice Guideline
13%
Health Service
13%
Health Care Personnel
12%
Hospital
11%
Malignant Neoplasm
11%
Outpatient
10%
Human Immunodeficiency Virus
10%
Diabetes Mellitus
10%
Case-Control Study
9%
Comorbidity
9%
Medline
9%
Mortality Rate
9%
Long Term Care
9%
Health Survey
9%
Health Literacy
9%
Head Injury
9%
Pilot Study
9%
Emergency Ward
9%
Cochrane Library
8%
Chronic Kidney Failure
8%
Psychometry
8%
Health Status
8%
Adolescent
8%
Cigarette Filter
8%
Cardiovascular Disease
8%
Body Mass
8%
Supplementation
7%
Spinal Cord Injury
7%
Gender Difference
7%
Infection
7%
Mental Health
7%
Independent Practice Association
7%
Brain Ischemia
7%
Metabolic Syndrome X
6%
Receiver Operating Characteristic
6%
Self Care
6%
Teaching Hospital
6%
Cerebrovascular Accident
6%
Adverse Event
6%
Hyperlipidemia
6%
Multivariate Logistic Regression Analysis
6%
Injury Severity
6%
Depression
5%
Correlation Coefficient
5%
Severe Acute Respiratory Syndrome
5%
Body Composition
5%
Embase
5%
International Classification of Functioning, Disability and Health
5%
Internal Consistency
5%
Shared Decision-Making
5%
Blood Pressure
5%
Intensive Care Unit
5%
Placebo
5%
Health Care Utilization
5%
Non Insulin Dependent Diabetes Mellitus
5%
Chronic Disease
5%
Hemodialysis
5%
Test Retest Reliability
5%
Proportional Hazards Model
5%